IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy

Wergeland, Ida; Pullar, Nadine Durema; Aßmus, Jörg; Ueland, Thor; Tonby, Kristian; Feruglio, Siri Laura; Kvale, Dag; Damås, Jan Kristian; Aukrust, Pål; Mollnes, Tom Eirik; Dyrhol‐Riise, Anne Ma

doi:10.1016/j.jinf.2014.12.019

Cited by 75 publications

(67 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum levels of the chemokine IP-10 (CXCL10) have demonstrated diagnostic value in differentiating between active TB and LTBI and to decline with treatment [11, 20, 54, 55]. In contrast to these reports, despite significant differences in IP-10 levels between fast and slow responders in our study, baseline levels of IP-10 alone showed relatively low sensitivity as a predictor of response to treatment.…”

Section: Discussioncontrasting

confidence: 91%

A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis

et al. 2017

View full text Add to dashboard Cite

ObjectiveTo identify plasma markers predictive of therapeutic response in patients with multidrug resistant tuberculosis (MDR-TB).MethodsFifty HIV-negative patients with active pulmonary MDR-TB were analysed for six soluble analytes in plasma at the time of initiating treatment (baseline) and over six months thereafter. Patients were identified as sputum culture positive or negative at baseline. Culture positive patients were further stratified by the median time to sputum culture conversion (SCC) as fast responders (< 76 days) or slow responders (≥ 76 days). Chest X-ray scores, body mass index, and sputum smear microscopy results were obtained at baseline.ResultsUnsupervised hierarchical clustering revealed that baseline plasma levels of IP-10/CXCL10, VEGF-A, SAA and CRP could distinguish sputum culture and cavitation status of patients. Among patients who were culture positive at baseline, there were significant positive correlations between plasma levels of CRP, SAA, VEGF-A, sIL-2Rα/CD40, and IP-10 and delayed SCC. Using linear discriminant analysis (LDA) and Receiver Operating Curves (ROC), we showed that a combination of MCP-1/CCL2, IP-10, sIL-2Rα, SAA, CRP and AFB smear could distinguish fast from slow responders and were predictive of delayed SCC with high sensitivity and specificity.ConclusionPlasma levels of specific chemokines and inflammatory markers measured before MDR-TB treatment are candidate predictive markers of delayed SCC. These findings require validation in a larger study.

show abstract

Section: Discussioncontrasting

confidence: 91%

A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Moreover, increased IP-10 serum levels are part of the biomarker profile characterizing the early onset of RRs (12,13). Levels of IP-10 decline again during antireactional therapy (13), similar to what has been described during tuberculosis treatment (14). With respect to the humoral immune response, IgM directed against the M. leprae-specific phenolic glycolipid I (PGL-I), although not informative for the identification of RR onset (13), represents a useful biomarker for monitoring the efficacy of treatment of leprosy (reactions), since IgM levels drop when reactions are effectively subdued (13).…”

supporting

confidence: 55%

Field-Friendly Test for Monitoring Multiple Immune Response Markers during Onset and Treatment of Exacerbated Immunity in Leprosy

Corstjens

Hooij

Fat

et al. 2016

Clin Vaccine Immunol

View full text Add to dashboard Cite

bAcute inflammatory reactions represent the major cause of irreversible neuropathy in leprosy. These tissue-destroying episodes have considerable overlap with acute immunological complications (flares) in several chronic (autoimmune) diseases that similarly warrant early detection. However, the lack of diagnostic tests impedes early diagnosis of these reactions. Here, we evaluated a user-friendly multiplex lateral flow assay for the simultaneous detection of IP-10 and anti-phenolic glycolipid I antibodies for longitudinally monitoring early onset and treatment of leprosy reactions.

show abstract

“…Therefore, to more accurately distinguish between these two stages, the selective combination of immune response genes has been under study. Among them, the protein levels of CXCL10 (IP-10; Tonby et al, 2015; Wergeland et al, 2015; Xiong et al, 2016; regulated under IFN-γ) and levels of mRNA Kim et al, 2015 or protein (Jeong et al, 2015; Lee et al, 2015a) for CXCL9, CXCL10, and CXCL11 have been pointed out by other researchers. These studies were mostly performed with blood mononuclear cells after stimulation with Mtb-specific antigens.…”

Section: Discussionmentioning

confidence: 94%

“…IFN-γ and CXCL10 (Holm et al, 2014; Latorre et al, 2014; Jeong et al, 2015; Tonby et al, 2015; Wergeland et al, 2015) are already well-known major biomarkers for TB. Our results are in agreement with those of previous studies, and are not surprising given that CXCL10 is known to be under the regulation of IFN-γ.…”

Section: Discussionmentioning

confidence: 99%

Unique Chemokine Profiles of Lung Tissues Distinguish Post-chemotherapeutic Persistent and Chronic Tuberculosis in a Mouse Model

Park

Baek

Cho

et al. 2017

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

There is a substantial need for biomarkers to distinguish latent stage from active Mycobacterium tuberculosis infections, for predicting disease progression. To induce the reactivation of tuberculosis, we present a new experimental animal model modified based on the previous model established by our group. In the new model, the reactivation of tuberculosis is induced without administration of immunosuppressive agents, which might disturb immune responses. To identify the immunological status of the persistent and chronic stages, we analyzed immunological genes in lung tissues from mice infected with M. tuberculosis. Gene expression was screened using cDNA microarray analysis and confirmed by quantitative RT-PCR. Based on the cDNA microarray results, 11 candidate cytokines genes, which were obviously up-regulated during the chronic stage compared with those during the persistent stage, were selected and clustered into three groups: (1) chemokine genes, except those of monocyte chemoattractant proteins (MCPs; CXCL9, CXCL10, CXCL11, CCL5, CCL19); (2) MCP genes (CCL2, CCL7, CCL8, CCL12); and (3) TNF and IFN-γ genes. Results from the cDNA microarray and quantitative RT-PCR analyses revealed that the mRNA expression of the selected cytokine genes was significantly higher in lung tissues of the chronic stage than of the persistent stage. Three chemokines (CCL5, CCL19, and CXCL9) and three MCPs (CCL7, CCL2, and CCL12) were noticeably increased in the chronic stage compared with the persistent stage by cDNA microarray (p < 0.01, except CCL12) or RT-PCR (p < 0.01). Therefore, these six significantly increased cytokines in lung tissue from the mouse tuberculosis model might be candidates for biomarkers to distinguish the two disease stages. This information can be combined with already reported potential biomarkers to construct a network of more efficient tuberculosis markers.

show abstract

IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy

Abstract: IP-10 distinguished with high accuracy active TB from LTBI irrespective of HIV infection and declined during anti-TB chemotherapy. Plasma IP-10 may serve as a diagnostic biomarker to differentiate between the stages of TB infection and for monitoring therapy efficacy.

Cited by 75 publications

References 48 publications

A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis

A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis

Field-Friendly Test for Monitoring Multiple Immune Response Markers during Onset and Treatment of Exacerbated Immunity in Leprosy

Unique Chemokine Profiles of Lung Tissues Distinguish Post-chemotherapeutic Persistent and Chronic Tuberculosis in a Mouse Model

Contact Info

Product

Resources

About